Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivatrotamab - Y-mAbs Therapeutics

Next Previous
Drug Profile

Nivatrotamab - Y-mAbs Therapeutics

Alternative Names: Hu3F8 bispecific antibody - Y-mAbs Therapeutics; Hu3F8-BsAb (GD2xCD3); huGD2-BsAb

Latest Information Update: 21 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Y-mAbs Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Neuroblastoma; Osteosarcoma; Small cell lung cancer; Solid tumours
  • No development reported Ewing's sarcoma

Most Recent Events

  • 08 Apr 2022 Y-mAbs Therapeutics terminates a phase I/II trial in Small cell lung cancer (Metastatic disease, Second-line therapy or greater, Recurrent) in USA due to business priorities (SC) (NCT04750239)
  • 20 Oct 2021 Y-mAbs Therapeutics terminates phase I/II trial in Osteosarcoma (In adolescents, In adults, In children, In the elderly, Second-line therapy or greater) in USA (IV) (NCT03860207)
  • 16 Aug 2021 Phase-I/II clinical trials in Small cell lung cancer (Metastatic disease, Second-line therapy or greater, Recurrent) in USA (SC) (NCT04750239)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top